Compare TAYD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAYD | CHRS |
|---|---|---|
| Founded | 1955 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.2M | 177.7M |
| IPO Year | 1995 | 2014 |
| Metric | TAYD | CHRS |
|---|---|---|
| Price | $59.98 | $1.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $70.00 | $5.51 |
| AVG Volume (30 Days) | 35.7K | ★ 1.1M |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $41,649,673.00 | N/A |
| Revenue This Year | $0.25 | $73.08 |
| Revenue Next Year | $19.78 | $30.94 |
| P/E Ratio | $23.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $40.50 | $1.09 |
| 52 Week High | $90.37 | $2.62 |
| Indicator | TAYD | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.75 | 48.00 |
| Support Level | $57.54 | $1.33 |
| Resistance Level | $62.42 | $1.51 |
| Average True Range (ATR) | 1.95 | 0.08 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 71.10 | 25.00 |
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.